NABTC Promotes First Brain Tumor Awareness Week

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 11
Volume 6
Issue 11

NEW YORK-The North American Brain Tumor Coalition (NABTC) kicked off the first Brain Tumor Awareness Week, October 19 to 25, 1997. The national event is designed to educate the public about the impact of brain tumors, as well as highlight the need for increased research funding.

NEW YORK—The North American Brain Tumor Coalition (NABTC) kicked off the first Brain Tumor Awareness Week, October 19 to 25, 1997. The national event is designed to educate the public about the impact of brain tumors, as well as highlight the need for increased research funding.

Said Susan Weiner, PhD, chair of the NABTC, “Our goal is to draw greater attention to a debilitating and often fatal disease for which the causes are still uncertain.” Each year, she said, approximately 100,000 people in the United States will be diagnosed with a primary or metastatic brain tumor.

To raise awareness about the need for increased research funding on Capitol Hill, the NABTC scheduled a Congressional Luncheon to take place during Brain Tumor Awareness Week.

The NABTC is also issuing a Patient Resource Guide during Brain Tumor Awareness Week to help connect brain tumor patients and their families with the various support services, informational materials, and programs provided by the coalition’s eight member organizations. A free copy can be obtained by calling 1-800-753-5877.

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content